-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Objective: To study the early use of biological agents antirheumatic disease improvement (bDMARDs) idiopathic arthritis polyarticular juvenile untreated (JIA) influence the course of
.
.
Methods: The investigators analyzed polyarticular JIA patients (n = 400) participating in the Polyarticular JIA Start Time Optimization Study (STOP-JIA ) and a comparative cohort from the Children’s Arthritis and Rheumatism Research Alliance Registry (n = 248) ) Data .
Latent Class Trajectory Modeling ( LCTM ) is applied to determine subgroups of patients with different disease courses based on disease activity ( disease activity scores of 10 joints in clinical juvenile arthritis) within 12 months from baseline .
Latent Class Trajectory Modeling ( LCTM ) is applied to determine subgroups of patients with different disease courses based on disease activity ( disease activity scores of 10 joints in clinical juvenile arthritis) within 12 months from baseline .
Results: In the STOP-JIA study, 198 subjects ( 49.
5% ) received bDMARDs within 3 months of baseline assessment .
The LCTM analysis generated 3 potential categories, representing 3 different disease trajectories, which are characterized by slow, moderate or rapid improvement in disease activity over time .
Results: In the STOP-JIA study, 198 subjects ( 49.
5% ) received bDMARDs within 3 months of baseline assessment .
The LCTM analysis generated 3 potential categories, representing 3 different disease trajectories, which are characterized by slow, moderate or rapid improvement in disease activity over time .
Subjects in the rapid improvement trajectory acquired inactive disease within 6 months from baseline .
After adjusting for demographic characteristics, properties and clinical disease activity at baseline found acceptance bDMARDs patients treated ≤ baseline 3 months after baseline and > 3 months of starting bDMARDs compared to subjects in a rapid improvement trajectory than the slow improvement trajectory The odds are 3.
Conclusion: Conclusion: In untreated polyarticular JIA subjects, starting bDMARDs within 3 months of baseline assessment is associated with faster realization of inactive disease
Source:
Ong MS, Ringold S, Kimura Y, Schanberg LE, Tomlinson GA, Natter MD; CARRA Registry Investigators.
Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study.
Arthritis Rheumatol.
2021 Oct;73(10):1910-1920.
doi: 10.
Ong MS, Ringold S, Kimura Y, Schanberg LE, Tomlinson GA, Natter MD; CARRA Registry Investigators.
Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study.
Arthritis Rheumatol.
2021 Oct;73(10):1910-1920.
doi: 10.
1002/art.
41892.
Epub 2021 Aug 27.
PMID: 34105303.
Leave a message here
